The CEACAM protein is over-expressed on >95% of pancreatic cancer patients. CEACAM6 is also over-expressed in colon cancers, as well as breast, lung, ovarian cancers and certain childhood leukemias.
Studies using the CEACAM6 Mab have demonstrated high levels of effectiveness and efficacy in mouse models. The Antibody binds to the CEACAM6 oncogene and interferes with its function, promoting apoptosis. CEACAM6 Mab is highly targeted and humanized. Therefore the Mab is projected to have extremely low toxicity, resulting in a very safe and effective treatment for pancreatic cancer.
The antibody was designed as a humanized anti-CEACAM6 single chain variable fragment (scFv) based on the murine Mab 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. The scFv bound CEACAM6 with high affinity, exhibited cytotoxic activity and induced dose-dependent PARP-cleavage in KRas mutated and wild type pancreatic cancer cell lines. Murine PDA xenograft models treated with low doses of humanized scFv-PEG alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry of harvested tumors showed significant apoptosis, with inhibition of angiogenesis and proliferation.
CEACAM6 Mab is protected by Patent # 8038996. The patent claims allow for a method of treating various types of cancer using an anti-CEACAM6 monoclonal antibody that induces apoptosis in cancer cells.